Synairgen plc
('Synairgen' or the 'Company')
Grant of Options
Southampton, UK - 15 November 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 14 November 2023 the Board of Synairgen granted options ('Options') over 1,900,000 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 0.94 per cent. of the Company's issued share capital.
Following this grant, Synairgen has 18,940,446 options in issue, representing 9.41 per cent. of the Company's issued share capital.
Certain Options were issued to the recently recruited Chief Financial Officer and Chief Medical Officer respectively, the former a Director of the Company; the later a Persons Discharging Managerial Responsibilities ('PDMR'):
| | Options issued 14 Nov 2023 | Total options | Ordinary shares | Total interest | Percentage holding of fully diluted share capital |
| Directors | | | | | |
| Joseph Colliver | 750,000 | 750,000 | - | 750,000 | 0.34% |
| PDMRs | | | | | |
| Marcin Mankowski | 750,000 | 750,000 | - | 750,000 | 0.34% |
The Options are issued under the Company's Long Term Incentive Plan and are exercisable up to 13 November 2033, subject to the achievement of appropriate performance criteria which match the criteria for the 2022 award as set out on page 23 of the 2022 annual report.
The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.
For further enquiries, please contact:
Synairgen plc
Tel: + 44 (0) 23 8051 2800
Cavendish Capital Markets Limited (NOMAD and Joint Broker)
Geoff Nash, Charlie Beeson (Corporate Finance)
Sunila de Silva (ECM)
Tel: + 44 (0) 20 7220 0500
Deutsche Numis (Joint Broker)
Freddie Barnfield, Duncan Monteith, Euan Brown
Tel: + 44 (0) 20 7260 1000
ICR Consilium (Financial Media and Investor Relations)
Mary-Jane Elliott, Namrata Taak, Lucy Featherstone
cscsynairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5700
Notes for Editors
About Synairgen
Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
| a) | Name | Joseph Colliver |
| 2. | Reason for notification | |
| a) | Position / status | Chief Financial Officer |
| b) | Initial notification / amendment | Initial Notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Synairgen plc |
| b) | LEI | 213800IMMTOPPDF8HD24 |
| 4. | Details of the transaction(s): | |
| a) | Description of the financial instrument
Identification code
| Options over ordinary shares of 1p each
GB00B0381Z20 |
| b) | Nature of the transaction | Award of Options under the Company's share plans |
| c) | Price(s) and volume(s) | 750,000 Options awarded Exercise price of one pence |
| d) | Aggregated information Aggregated volume Price | n/a |
| e) | Date of the transaction | 14 November 2023 |
| f) | Place of the transaction | Outside a trading venue |
| 1. | Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA') | |
| a) | Name | Dr Marcin Mankowski |
| 2. | Reason for notification | |
| a) | Position / status | Chief Medical Officer |
| b) | Initial notification / amendment | Initial Notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Synairgen plc |
| b) | LEI | 213800IMMTOPPDF8HD24 |
| 4. | Details of the transaction(s): | |
| a) | Description of the financial instrument
Identification code
| Options over ordinary shares of 1p each
GB00B0381Z20 |
| b) | Nature of the transaction | Award of Options under the Company's share plans |
| c) | Price(s) and volume(s) | 750,000 Options awarded Exercise price of one pence |
| d) | Aggregated information Aggregated volume Price | n/a |
| e) | Date of the transaction | 14 November 2023 |
| f) | Place of the transaction | Outside a trading venue |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
